Products and Platforms
TCS ADD™
TCS ADD™: A Suite of Modern and Open Technology Platforms
Highlights
- Agentic AI in drug development struggles to scale, not because of technological limitations, but due to missing governance, accountability, and trust required for regulated, inspection-ready workflows.
- Unlike traditional AI, agentic AI can plan, coordinate, and manage multi-step processes across functions while maintaining human accountability in evidence-driven clinical and safety environments.
- Successful scaling requires designing for trust, lifecycle control, and human oversight from the start, ensuring that AI remains auditable, governed, and aligned with regulatory expectations.
On this page
On this pageinpage
From Pilots to Production
There is no shortage of AI activity in the drug development lifecycle — just a shortage of outcomes that matter. Across clinical development and pharmacovigilance, copilots and agents already help with drafting, reviews, and coding. Yet most of this work never makes it into core, inspection-ready workflows. Pilots keep multiplying. Scale doesn’t.
This isn’t a technology problem. The technology is largely good enough already. What’s missing is everything around it — governance, accountability, operating discipline, and trust. In regulated environments, intelligence without control is a dead end.
Why Agentic AI differs
Agentic AI changes the game because it is not just about answering prompts. Agents can plan work, maintain context across long-running processes, and coordinate with humans and other agents. That matters in drug development, where work is distributed, interdependent, and rarely finished in a single step.
Clinical development and safety are evidence businesses. [AP3.1][AS3.2]Decisions flow across functions, and every output ultimately ties back to a human accountable for it. Done right, agentic AI can operate across these workflows without breaking that chain of responsibility.
Why scale keeps failing
Most agentic experiments stall for very practical reasons:
- AI outputs quickly become part of the evidence trail —and must be auditable.
- Regulators still expect named individuals to review and sign.
- Models, prompts, and data change, but controls often do not.
- Teams struggle to decide when AI can proceed and when humans must intervene.
As one safety leader noted after a demo, “This looks impressive—but who signs when the inspector asks?” Until that question is addressed, scaling remains out of reach.
Most teams assume scale comes from better orchestration. That logic works in consumer tech. It breaks down fast in regulated environments. The mental model that actually holds up in Clinical and pharmacovigilance workflows looks like the above. This is the critical shift.
What makes Agentic AI scale?
What makes Agentic AI scale?
In regulated drug development, orchestration alone is never enough. Scale only shows up when trust, accountability, and lifecycle control are designed in from day one.
Without these layers, orchestration just helps you industrialise risk. With them, agentic AI becomes something teams can defend — to quality, regulators, and themselves.
Why this works
- Trust answers the inspection question: who is accountable?
- Accountability keeps humans clearly in charge of decisions.
- Lifecycle control allows humans to provide the necessary oversight, while not compromising on the benefits. Exactly when a human needs to intervene and how they intervene is the secret sauce.
This is why agentic AI does not need to be autonomous to be powerful. It needs to be governed by design.
Trust beats autonomy
The mistake many teams make is chasing autonomy too early. In regulated work, trust matters more than speed.
The stronger pattern is simple:
- Agents operate in clearly defined roles.
- Autonomy is configurable, not assumed.
- Every action is visible, logged, and reviewable.
- Humans stay in control of judgement-heavy decisions.
In other words, agents do not replace experts — they work under them. This mirrors how clinical and pharmacovigilance teams already operate, which is exactly why it scales.
Platforms matter
The truth is stand-alone agents do not scale. Every new use case reopens the same debates about validation, governance, and control. That is why many organisations are moving toward common foundations for agentic AI — standard ways to define roles, supervision, auditability, and lifecycle management. When done well, these foundations stay invisible. Users see better workflows, not more technology.
The bottom line
Agentic AI will become part of clinical development and pharmacovigilance — it is inevitable. The real question is whether it becomes another tool, or a dependable way to run regulated work.
The teams that succeed will not obsess over autonomy. They will design for trust, scale, and human accountability from day one. Get that right, and agentic AI stops being a pilot —becoming instead part of how drug development looks.
Success does not mean fully autonomous AI.
It looks like faster cycle times with confidence. Reduced rework. Less manual fatigue. Teams spending less time worrying about inspections and more time delivering outcomes.
Conclusion
Agentic AI in drug development is inevitable. Making it safe, repeatable, and scalable is the real challenge. Organisations that succeed will stop chasing clever tools and instead build governed, human+AI agentic workforces. When that shift happens, agentic AI will finally move out of pilot mode — and into the works.